{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:34:43Z","timestamp":1787243683789,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T00:00:00Z","timestamp":1576454400000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Portal vein thrombosis (PVT) is a common complication of cirrhosis. However, in patients with PVT and cirrhosis, there is no clear evidence supporting effective treatment modalities. In this study, we examined the effectiveness and safety of anticoagulation therapy using danaparoid sodium for PVT in patients with cirrhosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study assessed 52 cirrhotic patients with PVT treated with danaparoid sodium for 2\u2009weeks between November 2008 and September 2018. The primary outcome measure was the post-treatment status of PVT assessed by reduction in thrombus volume and safety of the therapeutic intervention. PVT status was evaluated with contrast-enhanced computed tomography (CECT). All patients received 1250\u2009units of danaparoid sodium twice daily by intravenous injection for 14\u2009days. Patients on antithrombin III (AT-III) combination therapy were additionally administered 1500\u2009units of AT-III on days 1\u20135 and days 8\u201312. Effectiveness was evaluated by CECT from between days 13 and 18. The secondary outcome measure was the prognosis of PVT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All patients showed reduction in PVT volume without complications. Return of plasma AT-III level to &gt;\u200970% during the treatment period contributes to \u226575% reduction of PVT volume. The prognosis in PVT patients depends on hepatic reserve capacity. When limited to Child-Pugh B and C liver cirrhosis patients, a\u2009\u2265\u200975% reduction of PVT volume improved the prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Danaparoid sodium-based anticoagulation therapy was effective and safe for PVT in patients with cirrhosis. Return of plasma AT-III level to the normal range during the treatment period contributes to reduction of PVT volume. A reduction of \u226575% in PVT volume may improve the prognosis of Child-Pugh B and C decompensated cirrhosis patients with PVT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-019-1140-8","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T15:03:48Z","timestamp":1576508628000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Danaparoid sodium-based anticoagulation therapy for portal vein thrombosis in cirrhosis patients"],"prefix":"10.1186","volume":"19","author":[{"given":"Takehiro","family":"Hayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Takatori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Horii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouki","family":"Nio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Terashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriho","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Kitahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Shimakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuniaki","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eishiro","family":"Mizukoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Toyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuto","family":"Kozaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,16]]},"reference":[{"issue":"1","key":"1140_CR1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jceh.2014.12.008","volume":"5","author":"YK Chawla","year":"2015","unstructured":"Chawla YK, Bodh V. Portal vein thrombosis. J Clin Exp Hepatol. 2015;5(1):22\u201340.","journal-title":"J Clin Exp Hepatol"},{"issue":"5","key":"1140_CR2","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1002\/hep.22772","volume":"49","author":"LD DeLeve","year":"2009","unstructured":"DeLeve LD, Valla DC, Garcia-Tsao G. American Association for the Study Liver D: vascular disorders of the liver. Hepatol. 2009;49(5):1729\u201364.","journal-title":"Hepatol"},{"issue":"2","key":"1140_CR3","doi-asserted-by":"publisher","first-page":"64","DOI":"10.4254\/wjh.v6.i2.64","volume":"6","author":"N Kinjo","year":"2014","unstructured":"Kinjo N, Kawanaka H, Akahoshi T, Matsumoto Y, Kamori M, Nagao Y, Hashimoto N, Uehara H, Tomikawa M, Shirabe K, et al. Portal vein thrombosis in liver cirrhosis. World J Hepatol. 2014;6(2):64\u201371.","journal-title":"World J Hepatol"},{"issue":"13","key":"1140_CR4","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.3748\/wjg.v12.i13.2115","volume":"12","author":"M Ogren","year":"2006","unstructured":"Ogren M, Bergqvist D, Bjorck M, Acosta S, Eriksson H, Sternby NH. Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. World J Gastroenterol. 2006;12(13):2115\u20139.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"1140_CR5","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1053\/gast.2001.21209","volume":"120","author":"B Condat","year":"2001","unstructured":"Condat B, Pessione F, Hillaire S, Denninger M-H, Guillin M-C, Poliquin M, Hadengue A, Erlinger S, Valla D. Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology. 2001;120(2):490\u20137.","journal-title":"Gastroenterology"},{"issue":"27","key":"1140_CR6","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.4254\/wjh.v7.i27.2774","volume":"7","author":"JG Stine","year":"2015","unstructured":"Stine JG, Shah PM, Cornella SL, Rudnick SR, Ghabril MS, Stukenborg GJ, Northup PG. Portal vein thrombosis, mortality and hepatic decompensation in patients with cirrhosis: a meta-analysis. World J Hepatol. 2015;7(27):2774\u201380.","journal-title":"World J Hepatol"},{"issue":"1","key":"1140_CR7","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jhep.2005.05.009","volume":"43","author":"R de Franchis","year":"2005","unstructured":"de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2005;43(1):167\u201376.","journal-title":"J Hepatol"},{"issue":"7","key":"1140_CR8","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nrgastro.2014.36","volume":"11","author":"X Qi","year":"2014","unstructured":"Qi X, Han G, Fan D. Management of portal vein thrombosis in liver cirrhosis. Nat Rev Gastroenterol Hepatol. 2014;11(7):435\u201346.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"1140_CR9","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/hepr.12400","volume":"45","author":"N Naeshiro","year":"2015","unstructured":"Naeshiro N, Aikata H, Hyogo H, Kan H, Fujino H, Kobayashi T, Fukuhara T, Honda Y, Nakahara T, Ohno A, et al. Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis. Hepatol Res. 2015;45(6):656\u201362.","journal-title":"Hepatol Res"},{"issue":"1","key":"1140_CR10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/hepr.12895","volume":"48","author":"Y Nagaoki","year":"2018","unstructured":"Nagaoki Y, Aikata H, Daijyo K, Teraoka Y, Shinohara F, Nakamura Y, Hatooka M, Morio K, Nakahara T, Kawaoka T, et al. Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis. Hepatol Res. 2018;48(1):51\u20138.","journal-title":"Hepatol Res"},{"key":"1140_CR11","doi-asserted-by":"crossref","unstructured":"Hidaka H, Kokubu S, Sato T, Katsushima S, Izumi N, Igura T, Asahara S, Notsumata K, Osaki Y, Tsuji K, et al. Antithrombin III for portal vein thrombosis in patients with liver disease: a randomized, double-blind, controlled trial. Hepatol Res. 2017.","DOI":"10.1111\/hepr.12934"},{"key":"1140_CR12","doi-asserted-by":"crossref","unstructured":"Kojima S, Watanabe N, Koizumi J, Kokubu S, Murashima N, Matsutani S, Obara K. Current status of portal vein thrombosis in Japan: results of a questionnaire survey by the Japan Society for Portal Hypertension. Hepatol Res. 2017.","DOI":"10.1111\/hepr.12983"},{"issue":"1","key":"1140_CR13","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12876-017-0668-8","volume":"17","author":"S Fujiyama","year":"2017","unstructured":"Fujiyama S, Saitoh S, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Suzuki F, Arase Y, et al. Portal vein thrombosis in liver cirrhosis: incidence, management, and outcome. BMC Gastroenterol. 2017;17(1):112.","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"1140_CR14","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S1072-7515(00)00292-1","volume":"191","author":"SG Frangos","year":"2000","unstructured":"Frangos SG, Chen AH, Sumpio B. Vascular drugs in the new millennium. J Am Coll Surg. 2000;191(1):76\u201392.","journal-title":"J Am Coll Surg"},{"issue":"1","key":"1140_CR15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/230949900901700102","volume":"17","author":"J Nakase","year":"2009","unstructured":"Nakase J, Toribatake Y, Mouri Y, Seki H, Kitaoka K, Tomita K. Heparin versus danaproid for prevention of venous thromboembolism after hip surgery. J Orthop Surg (Hong Kong). 2009;17(1):6\u20139.","journal-title":"J Orthop Surg (Hong Kong)"},{"key":"1140_CR16","volume-title":"WC: International Union against Cancer (UICC) TNM classification of malignant tumours","author":"LH Sobin","year":"2009","unstructured":"Sobin LH. WC: International Union against Cancer (UICC) TNM classification of malignant tumours. 7th ed. New York: Wiley; 2009.","edition":"7"},{"issue":"1","key":"1140_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1443-1661.2009.00929.x","volume":"22","author":"T Tajiri","year":"2010","unstructured":"Tajiri T, Yoshida H, Obara K, Onji M, Kage M, Kitano S, Kokudo N, Kokubu S, Sakaida I, Sata M, et al. General rules for recording endoscopic findings of esophagogastric varices (2nd edition). Dig Endosc : Official J Japan Gastroenterol Endosc Soc. 2010;22(1):1\u20139.","journal-title":"Dig Endosc : Official J Japan Gastroenterol Endosc Soc"},{"issue":"10","key":"1140_CR18","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1002\/lt.20869","volume":"12","author":"J Bauer","year":"2006","unstructured":"Bauer J, Johnson S, Durham J, Ludkowski M, Trotter J, Bak T, Wachs M. The role of TIPS for portal vein patency in liver transplant patients with portal vein thrombosis. Liver Transpl. 2006;12(10):1544\u201351.","journal-title":"Liver Transpl"},{"issue":"4","key":"1140_CR19","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost : JTH. 2005;3(4):692\u20134.","journal-title":"J Thromb Haemost : JTH"},{"issue":"7","key":"1140_CR20","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.cgh.2012.01.012","volume":"10","author":"MG Delgado","year":"2012","unstructured":"Delgado MG, Seijo S, Yepes I, Achecar L, Catalina MV, Garcia-Criado A, Abraldes JG, de la Pena J, Banares R, Albillos A, et al. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clinical Gastroenterol Hepatol : Official Clin Pract J Am Gastroenterol Assoc. 2012;10(7):776\u201383.","journal-title":"Clinical Gastroenterol Hepatol : Official Clin Pract J Am Gastroenterol Assoc"},{"issue":"6","key":"1140_CR21","doi-asserted-by":"publisher","first-page":"686","DOI":"10.3109\/00365521.2012.674972","volume":"47","author":"H Maruyama","year":"2012","unstructured":"Maruyama H, Takahashi M, Shimada T, Yokosuka O. Emergency anticoagulation treatment for cirrhosis patients with portal vein thrombosis and acute variceal bleeding. Scand J Gastroenterol. 2012;47(6):686\u201391.","journal-title":"Scand J Gastroenterol"},{"issue":"6","key":"1140_CR22","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1007\/s10620-012-2548-y","volume":"58","author":"KT Werner","year":"2013","unstructured":"Werner KT, Sando S, Carey EJ, Vargas HE, Byrne TJ, Douglas DD, Harrison ME, Rakela J, Aqel BA. Portal vein thrombosis in patients with end stage liver disease awaiting liver transplantation: outcome of anticoagulation. Dig Dis Sci. 2013;58(6):1776\u201380.","journal-title":"Dig Dis Sci"},{"issue":"6","key":"1140_CR23","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1111\/j.1478-3231.2012.02785.x","volume":"32","author":"M Senzolo","year":"2012","unstructured":"Senzolo M. T MS, Rossetto V, Burra P, Cillo U, Boccagni P, Gasparini D, Miotto D, Simioni P, Tsochatzis E et al: prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis. Liver Int : Official J Int Assoc Study Liver. 2012;32(6):919\u201327.","journal-title":"Liver Int : Official J Int Assoc Study Liver"},{"issue":"6","key":"1140_CR24","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/MCG.0b013e3181b3ab44","volume":"44","author":"L Amitrano","year":"2010","unstructured":"Amitrano L, Guardascione MA, Menchise A, Martino R, Scaglione M, Giovine S, Romano L, Balzano A. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol. 2010;44(6):448\u201351.","journal-title":"J Clin Gastroenterol"},{"issue":"5","key":"1140_CR25","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/gut.2004.042796","volume":"54","author":"C Francoz","year":"2005","unstructured":"Francoz C, Belghiti J, Vilgrain V, Sommacale D, Paradis V, Condat B, Denninger MH, Sauvanet A, Valla D, Durand F. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut. 2005;54(5):691\u20137.","journal-title":"Gut"},{"issue":"1","key":"1140_CR26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ejim.2014.12.002","volume":"26","author":"X Qi","year":"2015","unstructured":"Qi X, De Stefano V, Li H, Dai J, Guo X, Fan D. Anticoagulation for the treatment of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis of observational studies. Eur J Intern Med. 2015;26(1):23\u20139.","journal-title":"Eur J Intern Med"},{"issue":"8","key":"1140_CR27","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1207541","volume":"368","author":"G Agnelli","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI, Investigators P-E. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699\u2013708.","journal-title":"N Engl J Med"},{"issue":"26","key":"1140_CR28","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","volume":"363","author":"R Bauersachs","year":"2010","unstructured":"Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499\u2013510.","journal-title":"N Engl J Med"},{"issue":"15","key":"1140_CR29","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","volume":"369","author":"HR Buller","year":"2013","unstructured":"Buller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406\u201315.","journal-title":"N Engl J Med"},{"issue":"1","key":"1140_CR30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12916-018-1069-8","volume":"16","author":"X Qi","year":"2018","unstructured":"Qi X, Guo X, Yoshida EM, Mendez-Sanchez N, De Stefano V, Tacke F, Mancuso A, Sugawara Y, Yang SS, Teschke R, et al. Transient portal vein thrombosis in liver cirrhosis. BMC Med. 2018;16(1):83.","journal-title":"BMC Med"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-019-1140-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12876-019-1140-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-019-1140-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T10:13:24Z","timestamp":1613124804000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-019-1140-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1140"],"URL":"https:\/\/doi.org\/10.1186\/s12876-019-1140-8","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"22 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study\u2019s treatment strategy and protocol were approved by the Institutional Review Board of Kanazawa University Hospital and all patients provided written informed consent to participate in the study. The study was conducted in accordance with the tenets of the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"217"}}